Ligand pharmaceuticals inc LGND.US 總覽分析
LGND 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
LGND 近期報酬表現
-2.94%
Ligand pharmaceuticals inc
1.31%
同產業平均
0.58%
S&P500
與 LGND 同產業的標的表現
- TXG 10x genomics inc價值 2 分趨勢 2 分波段 5 分籌碼 3 分股利 1 分查看更多
LGND 公司資訊
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter's Nexterone, and Acrotech Biopharma's Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.